MITO - 23
Recurrent ovarian,
primary peritoneal or
fallopian tube cancers
of BRCA mutated or
BRCAness phenotype
patients
II line chemotherapy
(physician choice):
- PLD 40 mg/mq d1 q28;
- Topotecan 4 mg/mq d1,8,15 q 28
- Weekly Paclitaxel 80 mg/mq d1,8,15 q28
-
Gemcitabine 1000 mg/mq gg1,8,15 q28
-
Carboplatin AUC 5 g 1 q 21
Randomized phase III
Trabectedin 1.3 mg/mq d1 q
21 in 3 hours (central line)
Random1.1
STRATIFICATION CRITERIA:
Measurable Disease
Platinum Sensitivity
Number of Previous CHT Lines (<3 vs >3)
BRCA status
